Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alcohol + cocaine refers to the concurrent use of ethanol (alcohol) and cocaine. When these substances are used together, the liver metabolizes them into a unique psychoactive compound called cocaethylene. Cocaethylene has similar stimulant properties to cocaine but is more cardiotoxic and has a longer half-life, leading to prolonged and intensified psychoactive effects compared to either drug alone[1][2][3]. The combination increases dopamine and serotonin levels by blocking their reuptake in the brain, which enhances euphoria but also raises risks for impulsivity, aggression, anxiety, depression, heart attack, stroke, seizures, liver damage, and sudden death[1][2][3][4]. The combined use is associated with higher rates of polysubstance abuse disorders and significantly greater risk of overdose or fatal cardiovascular events than using either substance alone[2][5]. There are no pharmaceutical developers or manufacturers for this combination; it arises from recreational or illicit co-use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alcohol + cocaine.